Cytoprotective activities of kinetin purine isosteres

Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

MAKOVÁ Barbara MIK Václav LIŠKOVÁ Barbora GONZALEZ Gabriel VÍTEK Dominik MEDVEDÍKOVÁ Martina MONFORT Beata RUČILOVÁ Veronika KADLECOVÁ Alena KHIRSARIYA Prashant BARREIRO Zoila Gándara HAVLÍČEK Libor ZATLOUKAL Marek SOURAL Miroslav PARUCH Kamil D'AUTRÉAUX Benoit HAJDÚCH Marián STRNAD Miroslav VOLLER Jiří

Year of publication 2021
Type Article in Periodical
Magazine / Source Bioorganic and Medicinal Chemistry
MU Faculty or unit

Faculty of Science

Citation
Web https://doi.org/10.1016/j.bmc.2021.115993
Doi http://dx.doi.org/10.1016/j.bmc.2021.115993
Keywords Cytokinin; Kinetin; bioisostery - Friedreichs ataxia; Mitoprotection - familial dysautonomia; Neuroprotection
Description Kinetin (N-6-furfuryladenine), a plant growth substance of the cytokinin family, has been shown to modulate aging and various age-related conditions in animal models. Here we report the synthesis of kinetin isosteres with the purine ring replaced by other bicyclic heterocycles, and the biological evaluation of their activity in several in vitro models related to neurodegenerative diseases. Our findings indicate that kinetin isosteres protect Friedreich's ataxia patient-derived fibroblasts against glutathione depletion, protect neuron-like SH-SY5Y cells from glutamate-induced oxidative damage, and correct aberrant splicing of the ELP1 gene in fibroblasts derived from a familial dysautonomia patient. Although the mechanism of action of kinetin derivatives remains unclear , our data suggest that the cytoprotective activity of some purine isosteres is mediated by their ability to reduce oxidative stress. Further, the studies of permeation across artificial membrane and model gut and blood-brain barriers indicate that the compounds are orally available and can reach central nervous system. Overall, our data demonstrate that isosteric replacement of the kinetin purine scaffold is a fruitful strategy for improving known biological activities of kinetin and discovering novel therapeutic opportunities.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info